Unique ID issued by UMIN | UMIN000001860 |
---|---|
Receipt number | R000002230 |
Scientific Title | Multicenter phase I trial of outpatient chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma |
Date of disclosure of the study information | 2009/04/08 |
Last modified on | 2017/04/17 07:33:50 |
Multicenter phase I trial of outpatient chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma
Phase I trial of outpatient chemotherapy with docetaxel and nedaplatin for oral cancer
Multicenter phase I trial of outpatient chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma
Phase I trial of outpatient chemotherapy with docetaxel and nedaplatin for oral cancer
Japan |
Oral squamous cell carcinoma
Oral surgery |
Malignancy
NO
To evaluate the safety dose of outpatient chemotherapy with docetaxel and nedaplatin for patients with unresectable or recurrent oral squamous cell carcinoma
Safety
Exploratory
Explanatory
Phase I
Safety of outpatient chemotherapy with docetaxel and nedaplatin for patients with unresectable or recurrent oral squamous cell carcinoma
Clinical and histopathological effect of outpatient chemotherapy with docetaxel and nedaplatin for patients with unresectable or recurrent oral squamous cell carcinoma
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Docetaxel is administered intravenously for 1 h on day1. After completion of the docetaxel infusion, nedaplatin is administered intravenously for another hour followed by 1,000 ml or more hydration. The dose levels of biweekly chemotherapy with docetaxel and nedaplatin are 30/40, 30/50, and 35/50 (mg/m2).
20 | years-old | <= |
80 | years-old | >= |
Male and Female
(1) Case with oral squamous cell carcinoma histologically, (2) age between 20 and 80 years (patients aged >80 years were allowed if major organs functions was preserved), (3) Karnofsky Performance Status (PS) score of 2 or less (4) adequate bone marrow function (5) adequate hepatic function (6) adequate renal function (7) written informed consent.
Patients were excluded if they had active infections, active second malignancy, severe heart diseases, interstitial pneumonia or lung fibrosis, severe pleural effusion or pericardial effusion that required drainage, fever more than or equal to 38 C, symptomatic brain metastasis, severe psychological disease, and possible pregnancy.
18
1st name | |
Middle name | |
Last name | Etsuhide Yamamoto |
Kanazawa University Graduate School of Medical Science
Oral & Maxillofacial Surgery
13-1 Takaramachi, Kanazawa, Ishikawa
076-265-2444
hkurita@shinshu-u.ac.jp
1st name | |
Middle name | |
Last name | Hiroshi Kurita |
Shinshu University School of Medicine
Department of Dentistry and Oral surgery
3-1-1 Asahi, Matsumoto, Nagano
0263-37-2675
hkurita@shinshu-u.ac.jp
Chubu research group on oral cancer
Chubu research group on oral cancer
Self funding
NO
2009 | Year | 04 | Month | 08 | Day |
Unpublished
Terminated
2008 | Year | 04 | Month | 01 | Day |
2008 | Year | 04 | Month | 01 | Day |
2014 | Year | 03 | Month | 31 | Day |
2014 | Year | 09 | Month | 30 | Day |
2014 | Year | 09 | Month | 30 | Day |
2017 | Year | 09 | Month | 30 | Day |
2009 | Year | 04 | Month | 08 | Day |
2017 | Year | 04 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002230